Long-term Safety, Efficacy, and PROs: Phase 3 Study of Leuprolide Acetate 6-month IM Depot in Central Precocious Puberty
Six-month LA IM depot for 144 weeks demonstrated a sustained inhibition of the GnRH axis in children with CPP with an acceptable safety profile. Health-related quality of life was maintained, and PAH improved during ∼3 years of treatment.
Authors
- Bhuvana Sunil (ORCID: https://orcid.org/0000-0003-1105-7056)
- Alvina R. Kansra (ORCID: https://orcid.org/0000-0003-0811-622X)
- Karen Klein (ORCID: https://orcid.org/0000-0003-4619-5432)
- Sunil Nayak
- Ahmed M Soliman
- Nelly Mauras
Institutions
- AbbVie (United States) (US)
- Rady Children's Hospital-San Diego (US)
- Nemours Children's Health System (US)
- Diabetes & Endocrine Associates (US)
- Mary Bridge Children's Health Center (US)
- Sensory Processing Disorder Foundation (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1210/jendso/bvaf224
- Primary Topic
- Hypothalamic control of reproductive hormones
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AbbVie